Vortioxetine improves physical and cognitive symptoms in patients with post-COVID-19 major depressive episodes

Major Depressive Episodes (MDE) following COVID-19 are frequent, can have a characteristic clinical picture, and are associated with immune-inflammatory changes. Vortioxetine is known to improve physical and cognitive performance in patients with depression and shows anti-inflammatory and anti-oxida...

Full description

Saved in:
Bibliographic Details
Published in:European neuropsychopharmacology 2023-05, Vol.70, p.21-28
Main Authors: Di Nicola, Marco, Pepe, Maria, Montanari, Silvia, Spera, Maria Chiara, Panaccione, Isabella, Simonetti, Alessio, Sani, Gabriele
Format: Article
Language:English
Subjects:
Antidepressants
Antidepressive Agents - therapeutic use
Cognition
COVID-19
COVID-19 - complications
Depressive Disorder, Major - complications
Depressive Disorder, Major - drug therapy
Double-Blind Method
Female
Humans
Male
Mood disorders
Personalized medicine
Quality of Life
Retrospective Studies
SARS-CoV-2
Short Communication
Treatment Outcome
Vortioxetine - pharmacology
Vortioxetine - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Major Depressive Episodes (MDE) following COVID-19 are frequent, can have a characteristic clinical picture, and are associated with immune-inflammatory changes. Vortioxetine is known to improve physical and cognitive performance in patients with depression and shows anti-inflammatory and anti-oxidative activities. This study aimed to retrospectively evaluate the effects of vortioxetine after 1 and 3 months of treatment in 80 patients (44.4% males, 54±17.2 years) with post-COVID-19 MDE. The primary outcome was improvement in physical and cognitive symptoms measured by specific items of Hamilton Depression Rating Scale (HDRS) and Hamilton Anxiety Rating Scale (HARS), Short Form-36 Health Survey Questionnaire (SF-36), Digit Symbol Substitution Test (DSST), Perceived Deficits Questionnaire for Depression (PDQ-D5). Changes in mood, anxiety, anhedonia, sleep, and quality of life were also investigated, as well as the underlying inflammatory status. Results show that, alongside reduction of depressive symptoms (HDRS, p
ISSN:0924-977X
1873-7862
DOI:10.1016/j.euroneuro.2023.02.006